Aroa Biosurgery Limited Stock

Equities

ARX

NZARXE0001S1

Medical Equipment, Supplies & Distribution

Delayed Australian S.E. 11:09:03 2024-05-21 pm EDT 5-day change 1st Jan Change
0.495 AUD 0.00% Intraday chart for Aroa Biosurgery Limited +3.12% -40.36%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 69.07M 42.08M 63.11M Sales 2025 * 86.06M 52.43M 78.65M Capitalization 186M 114M 170M
Net income 2024 -10M -6.09M -9.14M Net income 2025 * -1M -609K -914K EV / Sales 2024 3.02 x
Net cash position 2024 * 26.56M 16.18M 24.28M Net cash position 2025 * 29.07M 17.71M 26.56M EV / Sales 2025 * 1.83 x
P/E ratio 2024
-19.6 x
P/E ratio 2025 *
-155 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.03%
More Fundamentals * Assessed data
Dynamic Chart
1 week+3.12%
Current month-1.00%
1 month-1.00%
3 months-13.91%
6 months-26.12%
Current year-40.36%
More quotes
1 week
0.48
Extreme 0.48
0.51
1 month
0.48
Extreme 0.475
0.55
Current year
0.48
Extreme 0.475
0.87
1 year
0.48
Extreme 0.475
1.02
3 years
0.48
Extreme 0.475
1.30
5 years
0.48
Extreme 0.475
1.75
10 years
0.48
Extreme 0.475
1.75
More quotes
Date Price Change Volume
24-05-21 0.495 0.00% 241 205
24-05-21 0.495 -1.00% 990,243
24-05-20 0.5 +1.01% 169,661
24-05-17 0.495 -1.00% 174,226
24-05-16 0.5 +4.17% 32,102

Delayed Quote Australian S.E., May 21, 2024 at 07:59 pm EDT

More quotes
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement and complex wounds. Its subsidiaries are Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5414 NZD
Average target price
1.113 NZD
Spread / Average Target
+105.63%
Consensus

Quarterly revenue - Rate of surprise

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW